Xuepin tablet and application of combination of Xuepin tablet and didrogesterone in preparation of medicine for treating endometrial hyperplasia

Through the combination of blood flat tablets and dedrouterone, the PI3K/Akt/mTOR signaling pathway is regulated, estrogen and inflammatory factors are reduced, and the treatment problem of endometrial hyperplasia is solved, and effective improvement of endometrial hyperplasia is achieved. and preventive treatment.

CN118948952AInactive Publication Date: 2024-11-15JIANGXI POZIN PHARMA
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202411055917.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-02
Publication Date
2024-11-15
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

No effective drugs have been found in the prior art to treat endometrial hyperplasia, and endometrial hyperplasia has a tendency to become cancerous. Early diagnosis and rational treatment are crucial to preventing and treating the progress of disease.

Method used

Using a combination of blood flat tablets and dedrouterone, a pharmaceutical composition is formed by adjusting the dosage and combination dosage form to treat endometrial hyperplasia, including 500-1g/kg/d of blood flat tablets. The drug and dedrouterone are administered at 2.09 mg/kg/d, and combined into tablets, capsules, granules, etc.

Benefits of technology

By regulating the PI3K/Akt/mTOR signaling pathway, estrogen levels and inflammatory factors are reduced, the symptoms of endometrial hyperplasia are improved, the endometrial thickness and gland count are reduced, the IL-6 and TNF-α levels are reduced, and the intrauterine treatment is achieved. The purpose of membrane hyperplasia.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118948952A_ABST
    Figure CN118948952A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of traditional Chinese medicines, and discloses a Xuepin tablet and application of combination of the Xuepin tablet and didrogesterone in preparation of a medicine for treating endometrial hyperplasia. It is found that the Xuepin tablet can effectively improve the general state of an endometrial hyperplasia rat, reduce the intimal conditions such as the intimal thickness and the gland number of the rat endometrial hyperplasia rat, reduce the IL-6 and TNF-alpha inflammatory factor level and reduce estrogen, and the improvement effect may be achieved by regulating PI3K / Akt / mTOR signal channels, lowering PI3K, Akt and mTOR protein and mRNA expression and reducing inflammatory factors, so that the rat endometrial hyperplasia rat endometrial hyperplasia can be inhibited, and the rat endometrial hyperplasia rat endometrial hyperplasia rat endometrial hyperplasia rat endometrial hyperplasia rat endometrial hyperplasia rat endometrial hyperplasia can be inhibited. Immunoreaction is adjusted, balance is maintained, and then the treatment purpose is achieved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of traditional Chinese medicines, and relates to a Xueping tablet, and use of a combination of a Xueping tablet and dydrogesterone in preparing a medicine for treating endometrial hyperplasia. Background Art

[0002] Endometrial hyperplasia refers to endometrial hyperplasia with endometrial glandular hyperplasia and / or increased glandular stroma ratio. It is a common gynecological disease with a certain tendency to cancer. It is generally believed that the pathogenic factors are related to long-term estrogen stimulation without progesterone antagonism. Clinical endometrial hyperplasia is more common in perimenopausal women, and the incidence in young women of childbearing age has also increased significantly in recent years. The main clinical manifestations of endometrial hyperplasia are abnormal uterine bleeding, such as prolonged menstruation, menorrhagia, intermenstrual bleeding and postmenopausal bleeding. Long-term and heavy bleeding may be complicated by anemia and infection. Patients of childbearing age may become infertile, and some patients may also undergo malignant transformation. 2%-10% of abnormal uterine bleeding and 3%-10% of postmenopausal bleeding are caused by endometrial hyperplasia. Because atypical hyperplasia in endometrial hyperplasia has a tendency and risk of cancer, understanding its pathogenesis, early diagnosis and reasonable treatment are crucial to prevent and control further progression of the disease.

[0003] Xueping tablets are Chinese patent medicines, composed of Rehmannia root, Rhubarb root, Radix Notoginseng, Cuttlebone, Rubia cordifolia, and Pollen Typhae. It has the effects of clearing away heat and removing blood stasis, stopping bleeding and regulating menstruation. Studies have found that Xueping tablets can improve the symptoms of uterine fibroid model rats by inhibiting the expression of ER and PR in uterine smooth muscle cells (Zhou Chaozhong et al., Study on the Anti-Rat Uterine Myoma Effect of Xueping Tablets [J], Strait Pharmacy, Issue 11, 2023). CN111012848A discloses the use of Xueping tablets in the preparation of drugs for the treatment of uterine ectopic. Xueping tablets reduce serum estradiol levels and uterine estrogen receptors, thereby inhibiting estrogen stimulation of the uterus and achieving the effect of anti-uterine ectopic. At present, no research and use of Xueping tablets in the preparation of drugs for the treatment of endometrial hyperplasia have been found. Summary of the invention

[0004] In view of the above technical problems, the present invention provides Xueping tablets and use of Xueping tablets in combination with dydrogesterone in the preparation of a medicament for treating endometrial hyperplasia.

[0005] To achieve the above purpose, the technical solution adopted by the present invention is as follows:

[0006] In a first aspect, the present invention provides use of Xueping tablets in preparing a medicament for treating endometrial hyperplasia.

[0007] In some embodiments, the dosage of the blood-level tablet is about 500-1 g / kg / d; more preferably, about 1 g / kg / d.

[0008] In a second aspect, the present invention provides a use of Xueping tablets in combination with dydrogesterone in the preparation of a medicament for treating endometrial hyperplasia.

[0009] In some embodiments, the dosage of the blood level tablet is about 500 mg / kg / d, and the daily dosage of dydrogesterone is about 2.09 mg / kg / d.

[0010] In a third aspect, the present invention provides a pharmaceutical composition comprising Xueping tablets and dydrogesterone.

[0011] In some embodiments, the pharmaceutical compositions can be packaged individually or mixed together to form a whole and then packaged.

[0012] In some embodiments, the pharmaceutical composition includes a pharmaceutically acceptable excipient.

[0013] In some embodiments, the dosage form of the pharmaceutical composition is tablets, pills, pellets, capsules, granules, powders, powders, pastes, solutions, suspensions, sprays, drops, emulsions; preferably tablets, capsules, granules, powders or solutions.

[0014] Compared with the prior art, the present invention has the following beneficial effects:

[0015] Animal experiments have found that Xueping tablets can effectively improve the general condition of rats with endometrial hyperplasia, reduce the endometrial thickness, gland number and other endometrial conditions of rats with endometrial hyperplasia, reduce the levels of IL-6 and TNF-α inflammatory factors, and reduce estrogen. This improvement may be achieved by regulating the PI3K / Akt / mTOR signaling pathway, downregulating PI3K, Akt, mTOR protein and mRNA expression, reducing inflammatory factors, regulating immune response, maintaining balance, and thus achieving the therapeutic purpose. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] Figure 1 HE staining results of uterine tissues of rats in each group (×200 times), including: A: Control group; B: Model group; C: DYG group; D: XPP-L group; E: XPP-M group; F: XPP-H group; G: XPP+DYG group.

[0017] Figure 2 The electrophoresis diagrams of PI3K, Akt, and mTOR-related protein expressions in the uterine tissues of rats in each group, including: A: Control group; B: Model group; C: DYG group; D: XPP-L group; E: XPP-M group; F: XPP-H group; G: XPP+DYG group. DETAILED DESCRIPTION

[0018] The present invention is described below through specific embodiments to make the technical solution of the present invention easier to understand and grasp, but the present invention is not limited thereto, and the described embodiments are only a part of the embodiments of the present invention, rather than all of the embodiments.

[0019] The endpoints and any value of the scope disclosed in this article are not limited to the accurate scope or value, and these scopes or values ​​should be understood to include values ​​close to these scopes or values. For numerical ranges, between the endpoint values ​​of each scope, between the endpoint values ​​of each scope and a separate point value, and between separate point values, one or more new numerical ranges can be combined with each other, and these numerical ranges should be considered as specifically disclosed in this article. Unless the context clearly indicates otherwise, the singular form "one", "a kind of" and "described" as used herein include singular and plural indicators. The numerical range described by the endpoint is included in all numerical values ​​and fractions within the corresponding range, as well as the described endpoint.

[0020] Herein, "about" means that the quantity or numerical range indicated is an approximation within the experimental variability (or statistical experimental error). In the present invention, the term "about" should have the meaning of within 10%, preferably within 5% of the specified value or range.

[0021] The "drug" described in the present invention comprises the aforementioned Xueping tablets or Xueping tablets and dydrogesterone (hereinafter referred to as active ingredients) and acceptable excipients. In a specific embodiment, the active ingredient described in the present invention is provided in the drug in an effective amount (e.g., a therapeutically effective amount).

[0022] The "pharmaceutically acceptable excipients" described in the present invention include inert diluents, dispersants and / or granulating agents, surfactants and / or emulsifiers, disintegrants, binders, preservatives, buffers, lubricants and / or oils. Excipients (such as cocoa butter), colorants, coating agents, sweeteners, flavoring agents and aromatics may also be present in the pharmaceutical composition.

[0023] The "medicament" described in the present invention can be prepared by any method known in pharmacy. Generally speaking, these preparation methods include associating the aforementioned active ingredient with a carrier or excipient and / or one or more other auxiliary ingredients, and then if necessary and / or desired, shaping and / or packaging the product into a desired single dose or multiple dose unit.

[0024] The "drug" of the present invention can be prepared according to known methods, such as the methods described in the general rules for preparation of the 16th edition of the Japanese Pharmacopoeia, the United States Pharmacopoeia and the 9th edition of the European Pharmacopoeia. It depends on the dosage form.

[0025] The active ingredient and pharmaceutically acceptable excipients in the "medicament" of the present invention will vary according to the identity, body shape and / or condition of the subject to be treated and further according to the administration route of the composition. The active ingredient may be contained between 0.1% and 100% (w / w) in the medicament.

[0026] "Treatment" as used herein, unless otherwise indicated, means reversing, alleviating, inhibiting the progression of, or preventing the condition or disorder or one or more symptoms of such condition or disorder to which the term applies, unless otherwise indicated. The term "treat" as used herein refers to the act of treating, as "treat" is defined immediately above.

[0027] The "effective amount" described in the present invention refers to an amount sufficient to induce a desired biological response. The effective amount of the active ingredients of the present invention may vary depending on factors such as the desired biological endpoint, the pharmacokinetics of the compound, the condition being treated, the mode of administration, and the age and health of the subject. In certain embodiments, the effective amount is a therapeutically effective amount. The effective amount is the amount of the first active ingredient described in the present invention in a single dose. In certain embodiments, the effective amount is the combined amount of the active ingredients described in the present invention in multiple doses.

[0028] The "therapeutically effective amount" described in the present invention is an amount sufficient to provide a therapeutic benefit in the treatment of a disease or sufficient to delay or minimize one or more symptoms associated with the disease. The therapeutically effective amount of a Chinese medicine composition or Chinese medicine extract means the amount of a therapeutic agent that provides a therapeutic benefit in the treatment of a disease alone or in combination with other therapies. The term "therapeutically effective amount" may encompass an amount that improves overall therapy, reduces or avoids symptoms, signs or causes of a disease and / or enhances the therapeutic efficacy of another therapeutic agent. In certain embodiments, a therapeutically effective amount is an amount sufficient to treat any disease or disease described.

[0029] The terms "subject" or "patient" as used in the present invention are well known in the art and are used interchangeably herein to refer to mammals, including dogs, cats, rats, mice, monkeys, cows, horses, goats, sheep, pigs, camels, and most preferably humans. The term does not denote a particular age or sex. Thus, both adult and newborn subjects, whether male or female, are encompassed.

[0030] Based on the embodiments of the present invention, all other embodiments obtained by those of ordinary skill in the art without creative efforts shall fall within the protection scope of the present invention. The experimental methods described in the following embodiments are all conventional methods unless otherwise specified; the reagents and materials are all commercially available unless otherwise specified.

[0031] 1 Experimental materials

[0032] 1.1 Experimental animals

[0033] 73 SPF-grade female SD rats at 6 weeks of age, with a body weight of 200 ± 10 g, were purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd. [SCXK (Beijing) 2021-0011], and were housed in the animal house of Beijing University of Chinese Medicine (SPF grade), 5 rats per cage. The breeding temperature was 22 ± 2 °C, the humidity was 5-15%, and a 12 h light / dark cycle was maintained. This experiment was approved by the Animal Experiment Ethics Committee of Beijing University of Chinese Medicine, with the approval number BUCM-2023020704-1091.

[0034] 1.2 Experimental drugs

[0035] The heat-clearing and blood-cooling formula - Xueping tablets (drug composition: Rehmannia glutinosa, Rheum palmatum, Sanguisorba officinalis, Panax notoginseng, Sepia seu cuttlefish bone, Rubia cordifolia, Typha angustifolia) was provided by Jiangxi Puzheng Pharmaceutical Co., Ltd., with the national drug approval number Z20060278; specification: each tablet weighs 0.35 g. The normal dosage for humans is: 4 tablets each time, three times a day.

[0036] Dydrogesterone tablets (drug composition: dydrogesterone) were purchased from Dongzhimen Hospital of Beijing University of Chinese Medicine, produced by Abbott Biologicals B.V. of the Netherlands, with the approval number: HJ20170221, specification: 10 mg per tablet. The normal dosage for humans is: 2 tablets each time, once a day.

[0037] 1.3 Experimental reagents

[0038] The main reagents required for this experiment are shown in Table 1.

[0039] Table 1 Main experimental reagents

[0040]

[0041] 1.4 Main instruments

[0042] The main instruments required for this experiment are shown in Table 2.

[0043] Table 2 Main experimental instruments

[0044]

[0045] 1.5 Main consumables

[0046] Cryopreservation tubes, syringes, iodine disinfectant (Hunan Kefu Medical Equipment Co., Ltd.), alcohol (Qingdao Haishi Hainuo Innov Disinfection Technology Co., Ltd.), normal saline (Sichuan Kelun Pharmaceutical Co., Ltd.), tissue forceps, tissue scissors, ophthalmic scissors, hemostatic forceps, needle holder, ophthalmic curved tweezers, ophthalmic straight tweezers (Shanghai Surgical Instrument Factory), sterile gauze, sterile cotton balls.

[0047] 2 Experimental methods

[0048] 2.1 Experimental drug preparation

[0049] Xueping tablet solution: Grind the Xueping tablet in a mortar and dissolve in distilled water, vortex to mix, shake well before use, prepare the solution with concentrations of 0.025g / mL, 0.05g / mL, and 0.1g / mL, and store in a refrigerator at 4°C for future use.

[0050] Dydrogesterone solution: Grind the dydrogesterone tablets in a mortar and dissolve them in 0.5% sodium carboxymethylcellulose solution, stir evenly to make a 0.418 mg / mL dydrogesterone solution. Store in a 4°C refrigerator for later use.

[0051] CMC-Na solution: Dissolve 0.5 g of sodium carboxymethyl cellulose (CMC-Na) in 100 ml of distilled water, and stir while heating to make it evenly dissolved to prepare a 0.5% CMC-Na solution. Store in a refrigerator at 1-4°C for future use.

[0052] 2.2 Preparation of rat model of endometrial hyperplasia

[0053] The EH animal model was established by estrogen loading method. After the rats were adaptively fed for 2 weeks, the estrous cycle of the rats was observed during these 2 weeks, and the rats with irregular estrous cycle were eliminated.

[0054] Rats were given 0.6 mg / kg of estradiol benzoate intramuscularly three times a week for 28 days. Vaginal epithelial exfoliated cell smears and Papanicolaou staining of rats in the model group were observed under continuous microscopy for 1 week, and rats with cyclical changes in keratinization rate were eliminated. Two rats were randomly selected from the remaining rats for laparotomy to obtain endometrial tissue, and endometrial pathological sections were performed. After HE staining and observation under a microscope, the endometrium in the model group showed proliferative changes, indicating that the model was successfully established.

[0055] 2.3 Animal grouping and drug administration

[0056] The rats with successful modeling were randomly divided into 6 groups: model group, high-, medium- and low-dose groups of Xueping Tablets, dydrogesterone group, and Xueping Tablets+progesterone group, with 10 rats in each group.

[0057] Dosage determination method: The clinical dosage of Xueping tablets for adults is 4.2g / d. The standard body weight of rats is 200g and the standard body weight of humans is 60kg. The equivalent dose is converted according to the body surface area conversion formula between humans and rats, and the dosage for rats is calculated. The specific administration method and dosage are as follows:

[0058] (1) Blank group: (Control group): The mice were intragastrically administered with 0.5% CMC-Na at a dose of 1 mg / 100 g / day, once a day, without any special treatment.

[0059] (2) Model group: 0.5% CMC-Na was intragastrically administered, 1 mg / 100 g / day, once a day, without any special treatment.

[0060] (3) Dydrogesterone group (DYG group): The patients were given dydrogesterone solution by oral gavage at a clinical equivalent dose of 2.09 mg / kg / day, once a day.

[0061] (4) Xuepingpian low-dose group (XPP-L group): The mice were given Xuepingpian solution by oral gavage at 1 / 2 the clinical dosage, 250 mg / kg / day, once a day.

[0062] (5) Xuepingpian medium-dose group (XPP-M group): The mice were given Xuepingpian solution by oral gavage at the clinical equivalent dosage, 500 mg / kg / day, once a day.

[0063] (6) Xuepingpian high-dose group (XPP-H group): The mice were given Xuepingpian solution by oral gavage at twice the clinical dosage, 1 g / kg / day, once a day.

[0064] (7) Xuepingpian + Dydrogesterone group (Xuepingpian + Dydrogesterone, XPP + DYG group): Xuepingpian and dydrogesterone were administered by intragastric administration according to the clinical equivalent dosage, 500 mg / kg / day of Xuepingpian + 2.09 mg / kg / day of dydrogesterone, once a day.

[0065] Drug intervention was started on the 29th day after model establishment, with oral administration once a day (10:00-12:00) for 28 consecutive days.

[0066] 2.4 Experimental materials collection and specimen handling

[0067] On the 29th day after administration, the general condition and behavioral characteristics of rats in each group were observed. The rats were fasted but not watered for 12 hours before sampling. After weighing, 1.5% pentobarbital was intraperitoneally injected to anesthetize the rats. The rats were placed on an ice box, and after opening the abdomen layer by layer, the uterus was fully exposed, and the uterus and ovaries were observed with the naked eye. The abdominal organs were pushed open with a cotton swab to expose the abdominal aorta, and a disposable blood collection needle was carefully and quickly inserted at a flat angle of <15 degrees. 4-5ml of abdominal aortic blood was drawn into a red anticoagulant tube, and placed in a 37C constant temperature incubator for half an hour, then placed in a centrifuge, and centrifuged at 4℃ for 10min (3000r / min). The upper serum was drawn into a pre-numbered 1.5mL EP tube, and then transferred to a -80℃ refrigerator for storage for enzyme-linked immunosorbent assay (ELISA) detection.

[0068] After blood collection, rats in each group were killed by cervical dislocation. The whole uterus was quickly removed under sterile conditions, rinsed with saline three times, dried with filter paper, weighed, photographed, and cut open at the bifurcation. One corner of the uterus was immediately placed in a cryovial and frozen in liquid nitrogen, and then stored in a -80°C refrigerator for subsequent protein blotting (WB) and fluorescence detection (Real Time Quantitative PCR, RT-qPCR). The other corner of the uterus was longitudinally cut open and quickly fixed in 4% paraformaldehyde fixative for immunohistochemical detection.

[0069] 2.5 Observation and testing indicators

[0070] 2.5.1 Observation of general condition of rats

[0071] During the experiment, the general conditions of the seven groups of rats were closely observed, such as mental state, reaction sensitivity, weight changes, mouth, nose, ear color, skin and hair color and quantity, food and water intake, excretion, vaginal secretions and perianal contamination, and detailed records were made.

[0072] 2.5.2 Uterine coefficient

[0073] The day after the last administration, the rats in each group were weighed and the body weight was recorded. The wet weight of the uterus (g) was weighed with a precision balance when the samples were collected, and the uterus coefficient was calculated according to the formula: uterus coefficient = uterus wet weight / rat body weight × 100%.

[0074] 2.5.3 Evaluation of endometrial tissue pathology

[0075] The rat uterine tissue was fixed with 4% paraformaldehyde fixative, and the cross-section of the uterine tissue was cut after 48 hours. The uterine tissue was routinely dehydrated, waxed, embedded, sliced ​​(5μm), stained with HE, and fixed. Two slices with good staining effect and relatively complete tissue were selected from each group. Pictures around the endometrium were collected under 40x, 100x and 200x microscopes. Image J 1.53 software was used for image analysis, endometrial morphology was observed, the number of glands was counted, and the endometrial thickness was measured. Four 100x fields of view were selected for each slice to take pictures and count the number of uterine glands in each field of view (pieces), and the average value was taken to obtain the number of glands. The endometrial thickness (μm) was measured, and 3 data were measured for each picture, and the average value was taken to obtain the endometrial thickness.

[0076] 2.5.4 Expression of inflammatory factors in rat serum

[0077] ELISA was used to detect the levels of IL-6 and TNF-α in rat serum. The specific steps are as follows:

[0078] (1) Rewarming: Move all reagents to room temperature (18-25°C) and equilibrate for at least 30 minutes, then prepare the reagents for later use.

[0079] (2) Sample addition: Set up blank wells (blank control wells without adding samples and enzyme-labeled reagents, and the rest of the steps are the same), standard wells, and test sample wells. Accurately add 50 μl of the standard well to the enzyme-labeled plate, add 40 μl of sample diluent to the test sample well, and then add 10 μl of the test sample. Add the sample to the bottom of the well, and shake gently to mix without touching the well.

[0080] (3) Add enzyme: Add 100 μl of enzyme-labeled reagent to each well, except for the blank well.

[0081] (4) Incubation: Seal the plate with a sealing film and incubate at 37°C for 60 min.

[0082] (5) Liquid preparation: Dilute the 20-fold concentrated washing solution with 20-fold distilled water and set aside.

[0083] (6) Washing: Carefully peel off the sealing film, discard the liquid in the wells, spin dry, fill each well with washing solution, let it stand for 30 seconds and then discard it. Repeat this process 5 times and spin dry.

[0084] (7) Color development: Add 50 μl of color developer A and 50 μl of color developer B to each well, shake gently to mix, and develop color for 15 minutes.

[0085] (8) Termination: Add 50 μl of stop solution to each well to terminate the reaction (the blue color immediately turns yellow).

[0086] (9) Measurement: Use the blank well as the zero setting, and measure the optical density (OD value) of each well in sequence at a wavelength of 450 nm. The measurement should be performed within 15 minutes after adding the stop solution.

[0087] (10) Data processing: The standard and sample values ​​can be subtracted from the blank well values ​​to draw a curve, set duplicate wells, and calculate the average value. Use the concentration of the standard as the ordinate and the OD value as the abscissa to draw a standard curve on a logarithmic coordinate paper. Use the professional curve making software "CurveExpert1.3" for analysis. According to the sample OD value, the corresponding concentration can be found from the standard curve.

[0088] 2.5.5 Expression of estrogen and progesterone in rat serum

[0089] ELISA kit was used to detect the content of progesterone and estrogen in rat serum. The specific steps were the same as above.

[0090] 2.5.6 Western Blot detection of PI3K / Akt / mTOR pathway-related protein expression in rat uterine tissue

[0091] 2.5.6.1 Rat uterine sample processing

[0092] (1) Take the uterine tissue sample out of the refrigerator, add lysis buffer to lyse it, grind it thoroughly using the magnetic bead method, centrifuge it at 12000 rpm at 4°C for 30 min, and collect the supernatant.

[0093] (2) Determination of protein concentration: Use BCA protein concentration determination kit.

[0094] (3) According to the concentration measurement results, 5× loading buffer and 1× PBS were added to adjust the protein concentration to ensure that the protein concentrations of different groups were consistent. After the concentration was adjusted, the samples were boiled in a 100°C metal bath for 10 min and stored at -80°C.

[0095] 2.5.6.2 Experimental operation

[0096] (1) Sample loading and electrophoresis: Load the processed sample in a total volume of 8 μl per well. Perform electrophoresis with 80V concentration gel, 120V separation gel, and constant voltage power supply for each gel; determine the position of the target protein based on the relative position of the pre-stained marker and the molecular weight of the target protein, and stop electrophoresis separation when the target protein is at the best resolution position in the lower 1 / 3 of the separation gel surface.

[0097] (2) Transfer: Soak the cut PVDF membrane in methanol for 10 seconds, then put it into new transfer solution for later use; take out the gel and cut the target band according to the marker, cut the PVDF membrane and filter paper of the same size as the PAGE gel, and soak the PVDF membrane and filter paper in the electrotransfer buffer. Place the black plate-fiber pad-filter paper-gel-PVDF membrane-filter paper-fiber pad-white plate in order, clamp the plate and put it into the transfer instrument, with the black plate facing the black negative electrode. Fill the transfer tank with electrotransfer solution and start the transfer. The transfer process is carried out at 4°C (ice bath), the transfer condition is a current of 200mA, and the transfer time is based on the molecular weight of the target band plus 25min.

[0098] (3) Blocking: Block the PVDF membrane with 3% skim milk (preparation: 3 g skim milk powder diluted with 1× TBST to 100 mL) and block on a shaker at room temperature for 1 h.

[0099] (4) Primary antibody: β-actin was diluted at 1:5000. Dilute the corresponding primary antibody with 3% skim milk, immerse the PVDF membrane in the primary antibody incubation solution, and incubate overnight at 4°C. PIK3 was diluted at 1:1000, AKT was diluted at 1:5000, and mTOR was diluted at 1:5000. After overnight incubation, take out and shake at room temperature for 15 minutes. After the end, wash off the excess primary antibody; wash the PVDF membrane thoroughly with 1×TBST 5 times, 5 minutes each time.

[0100] (5) Secondary antibody: dilute HRP-labeled secondary antibody with 1×TBST at a dilution of 1:20,000, immerse the PVDF membrane in the secondary antibody incubation solution, and incubate on a shaker at room temperature for 1 hour. After the incubation, wash away the excess secondary antibody; wash the PVDF membrane 5 times with 1×TBST, 5 minutes each time.

[0101] (6) Color exposure: Mix the enhancement solution in the ECL reagent and the stable peroxidase solution in a 1:1 ratio, place the membrane in the prepared luminescent solution and let it stand for 10-30 seconds, and then use a fully automatic chemiluminescence image analysis system for exposure.

[0102] (7) Membrane elution and regeneration: After exposure, wash the PVDF membrane with 1×TBST for 5 times, 5 min / time. Add an appropriate amount of membrane regeneration solution, soak the PVDF membrane in the membrane regeneration solution, and shake it at room temperature for 30 min for elution. After the end, wash away the excess membrane regeneration solution: wash the PVDF membrane with 1×TBST for 5 times, 5 min / time.

[0103] (8) Blocking, internal control incubation, secondary antibody incubation, and exposure were performed again. The specific procedures were the same as the above experimental procedures. β-actin was diluted 1:5000.

[0104] 2.5.6.3 Scanning and analysis

[0105] The film was scanned and the optical density of the target band was analyzed using Image J 1.53 software.

[0106] 2.5.7 RT-qPCR detection of PI3K / Akt / mTOR mRNA expression in rat uterine tissue

[0107] 2.5.7.1 Obtaining total RNA extract from uterine tissue

[0108] The tissue was taken out from the liquid nitrogen, placed in a pre-cooled mortar and added with liquid nitrogen for rapid grinding, and then the powder was put into a pre-cooled EP tube, 1 ml of Trizol was added to each tube, and the tube was blown several times with a gun and placed at room temperature for 5 minutes.

[0109] (1) Add chloroform at a ratio of 0.2 ml / ml Trizol, cover the centrifuge tube tightly, and shake the centrifuge tube vigorously by hand for 15 seconds until the fully emulsified solution becomes milky white. Leave it at room temperature for 2-3 minutes.

[0110] (2) Centrifuge at 12000 x g for 15 min at 4°C. The solution is divided into three layers from bottom to top: a light pink phenol layer, a middle white protein layer, and a clear aqueous phase. The RNA is in the aqueous phase, about 500 μl.

[0111] (3) Take the upper layer of water and place it in a new centrifuge tube. Add isopropanol at a ratio of 0.5 ml / ml Trizol and leave it at room temperature for 20 min.

[0112] (4) Centrifuge at 12000 g for 10 minutes at 4°C. The RNA will precipitate into a gelatinous layer.

[0113] (5) Discard the supernatant and add 75% ethanol (prepared with DEPC water) at a rate of 1 ml / ml Trizol solution.

[0114] (6) Gently invert the tube upside down and centrifuge at 7500 x g at 4°C for 5 min.

[0115] (7) Carefully discard the supernatant and dry at room temperature for 3 min.

[0116] (8) Dissolve RNA in 30-50ul DEPC water.

[0117] (9) Use a nucleic acid UV spectrophotometer to measure the OD value and concentration of the diluted RNA extract, determine the RNA purity, and calculate the RNA concentration.

[0118] (10) RNA samples were stored in a -80°C freezer for a long period of time.

[0119] 2.5.7.2 In vitro RNA inversion and Real-Time PCR

[0120] (1) Reverse transcription system

[0121] Using total RNA as template, reverse transcription and cRNA synthesis were performed. A 0.5 ml PCR tube was placed in an ice bath and various reagents were added. The mixture was gently mixed and stored at -20°C for later use after the reaction was completed. See Table 3 for details.

[0122] Table 3 Reverse transcription system

[0123]

[0124] (2) Real-Time PCR Quantification

[0125] The full-length sequence of the target gene mRNA was obtained from the GenBank database, and the primer sequence was designed using the primer and probe design software Primer 5.0. After Blast analysis, the primer sequence was specific. The primers used and the internal reference Actin primers are detailed in Table 4.

[0126] Table 4 Primer sequences

[0127]

[0128] Add the obtained cDNA into a 0.2 ml centrifuge tube, add reagents in sequence according to Table 5, mix well and place in the PCR instrument program reaction.

[0129] The PCR program cycle parameter settings were as follows: ① 94°C pre-denaturation, 2 min; ② 94°C denaturation, 5 s; ③ 60°C annealing, 30 s; ④ 72°C extension, 10 min; ②-③ were repeated for 45 cycles.

[0130] Table 5 PCR reaction system

[0131]

[0132] 2.5.7.3 Calculation method

[0133] Relative quantification 2 -ΔΔCT The results of the method analysis were obtained by using the Ct value of the target gene of each sample, that is, the Ct value of the housekeeping gene calibrant sample (GAPDH) of each sample, to obtain the delta Ct of the test sample, and using the approximate mean of the delta Ct-control group to obtain deltadelta Ct (-ΔΔCT), and the relative quantitative 2 was calculated. -ΔΔCT The gene expression ratio results were analyzed by the method.

[0134] 2.6 Statistics

[0135] SPSS22.0 statistical software was used for data processing. The experimental data obtained were all quantitative data. The Shapiro-Wilk test method was used to test the normality of the experimental data. The data that met the normality test were expressed as mean ± standard deviation (Mean ± SD), and the data that did not meet the normal distribution were expressed as median. When the data of each group met the normality and variance homogeneity, one-way ANOVA was used for inter-group comparison. The LSD test was used for homogeneous variance, and the non-parametric rank sum test of multiple independent samples was used for unequal variance. The test results were considered to be significant when P < 0.05.

[0136] 3 Results

[0137] 3.1 General characterization observations

[0138] After the modeling, the rats in the Control group were in good general condition, with good mental state, lively and active, sensitive reaction, normal breathing rate, shiny skin and fur, normal food intake and excretion, normal vaginal secretions, and no pollution around the anus. The rats in the Model group were generally in good condition, with restless spirit, active, light and dark skin and fur, some rats had local hair loss, less food and water intake, increased vaginal secretions, and no pollution around the anus.

[0139] After the administration began, the general conditions of the rats in each group tended to be stable, while the overall condition of the rats in the Model group was poor.

[0140] Mental anxiety, hyperactivity, occasional fighting, less food and water intake than other groups, dull fur, thin body. The mental state of rats in each drug-treated group improved, and the food and water intake increased compared with before. The state of rats in the dydrogesterone group, the medium-dose group of Xueping tablets, the high-dose group of Xueping tablets, and the Xueping tablets + dydrogesterone group improved compared with before, with shiny skin and fur, and local hair loss improved compared with before. During the drug-treated period, one rat in the low-dose group of Xueping tablets died.

[0141] 3.2 Results of uterine index determination of rats in each group

[0142] Compared with the Control group, the uterine index of rats in each group increased to varying degrees, and the difference was statistically significant (P < 0.05). Compared with the Model group, the uterine index of the XPP-H group and the XPP+DYG group showed a downward trend, but it did not reach statistical significance (P > 0.05), as shown in Table 6.

[0143] Table 6 Comparison of uterine index of rats in each group

[0144]

[0145] Note: Compared with the Control group, a P<0.05; compared with the Model group,b P<0.05; compared with DYG group, c P<0.05; compared with XPP-L group, d P<0.05; compared with XPP-M group, e P<0.05; compared with XPP-H group, f P<0.05.

[0146] 3.3 Observation of uterine pathological sections of rats in each group

[0147] Results Figure 1 The uterine muscle fibers of rats in the control group were arranged regularly, with inner rings and outer longitudinal lines, and the endometrium with clear and normal structure could be seen. The endometrial epithelial cells and glandular epithelial cells were tall columnar, the glands were densely arranged, the glandular cavities were of different sizes, secretory vacuoles were visible at the bottom of the cells, and the morphology of the muscle layer fibers was regular.

[0148] Compared with the Control group, the muscle fibers in the Model group were slightly hypertrophied and slightly disordered, and the endometrial structure was changed. The endometrial epithelial cells and glandular epithelial cells were low columnar. The endometrium was thickened, and the glands were single-layer or multi-layer columnar. The number was significantly increased and the glands were crowded compared with the Control group. Most rats had obvious eosinophil infiltration in the endometrium, and edema was common.

[0149] Compared with the Model group, the DYG group had fewer intimal epithelial cells and glandular epithelial cells, some of which were occasionally infiltrated with eosinophils, and edema was rare. Comparison between intervention groups: Compared with the DYG group, the intimal epithelial cells and glandular epithelial cells in the XPP-H group and the XPP+DYG group were monolayer, with secretory vacuoles with glycogen accumulation at the bottom of the cells, less inflammatory cell infiltration, and less edema.

[0150] 3.4 Comparison of the number of endometrial glands in each group of rats

[0151] Compared with the Control group, the number of endometrial glands in the Model group, DYG group, XPP-L group, and XPP+DYG group decreased, and the difference was statistically significant (P < 0.05). The number of glands in the XPP-M group and XPP-H group increased, and there was no significant difference compared with the Control group (P > 0.05). Compared with the Model group, the number of glands in the XPP+DYG group increased significantly, and the difference was statistically significant (P < 0.05). There was no significant difference in the number of glands in the other groups (P > 0.05). See Table 7 for details. Figure 1 .

[0152] Table 7 Results of determination of uterine morphological indexes of rats in each group

[0153]

[0154]

[0155] Note: Compared with the Control group, a P<0.05; compared with the Model group, b P<0.05; compared with DYG group, c P<0.05; compared with XPP-L group, d P<0.05; compared with XPP-M group, e P<0.05; compared with XPP-H group, f P<0.05.

[0156] 3.5 Comparison of endometrial thickness in rats of each group

[0157] Compared with the Control group, the endometrial thickness of rats in the Model group and the low-dose Xueping Tablet group increased, with statistically significant differences (P<0.05). Compared with the Model group, the endometrial thickness of each intervention group decreased to varying degrees, with statistically significant differences (P<0.05).

[0158] The comparison results of the intervention groups: Compared with the XPP-L group, the XPP-H group and the XPP+DYG group showed a significant reduction in the endometrium, with a statistically significant difference (P < 0.05). The XPP-L group, the XPP-M group, the XPP-H group, the XPP+DYG group and the DYG group showed the same improvement in the endometrium, with no significant difference (P > 0.05). See Table 7 for details. Figure 1 .

[0159] 3.6 Expression of serum inflammatory factors in rats in each group

[0160] The results are shown in Table 8. Compared with the Control group, the inflammatory factor IL-6 of rats in the Model group and XPP-L group was significantly increased, and compared with the Model group, the IL-6 of rats in the DYG group, XPP-M group, XPP-H group, and XPP+DYG group was decreased, and the difference was statistically significant (P < 0.05).

[0161] Comparison between treatment groups: Compared with the XPP-L group, the IL-6 level in the XPP+DYG group was significantly reduced, and the difference was statistically significant (P<0.05). Compared with the DYG group, the IL-6 level in the XPP+DYG group was significantly decreased, and the difference was statistically significant (P<0.05).

[0162] Compared with the Control group, the serum TNF-α levels in the Model group, XPP-L group, and XPP-M group were increased, with statistically significant differences (P<0.05). Compared with the Model group, the TNF-α levels in the DYG group, XPP-H group, and XPP+DYG group were decreased, with statistically significant differences (P<0.05).

[0163] Comparison between treatment groups: Compared with the XPP-L group, the TNF-α level in the XPP+DYG group was significantly decreased, and the difference was statistically significant (P<0.05). Compared with the XPP-M group, the serum TNF-α level in the XPP+DYG group was significantly decreased, and the difference was statistically significant (P<0.05).

[0164] Table 8 Comparison of serum inflammatory factor levels in rats in each group

[0165]

[0166] Note: Compared with the Control group, a P<0.05; compared with the Model group, b P<0.05; compared with DYG group, c P<0.05; compared with XPP-L group, d P<0.05; compared with XPP-M group, e P<0.05; compared with XPP-H group, f P<0.05.

[0167] 3.7 Serum estrogen and progesterone levels in rats of each group

[0168] The results are shown in Table 9. Compared with the Control group, the E2 levels in the Model group and the XPP-L group increased, and the difference was statistically significant (P < 0.05). Compared with the Model group, the E2 level in the XPP+DYG group decreased, and the difference was statistically significant (P < 0.05). Comparison between intervention groups: Compared with the XPP-L group, the E2 level in the XPP+DYG group was significantly reduced, and the difference was statistically significant (P < 0.05).

[0169] Compared with the Control group, except for the DYG group, the progesterone levels of the other groups were not significantly different, and the difference was not statistically significant (P>0.05). Compared with the Model group, the progesterone level of the DYG group increased significantly, and the difference was statistically significant (P<0.05). Compared with the intervention groups, the progesterone level of the DYG group was higher than that of the XPP-L group, XPP-M group, and XPP-H group, and the difference was statistically significant (P<0.05). Compared with the DYG group, the progesterone level of the XPP+DYG group was lower, but the difference was not statistically significant (P>0.05)

[0170] Table 9 Comparison of serum estrogen and progesterone levels in rats of each group

[0171]

[0172] Note: Compared with the Control group, aP<0.05; compared with the Model group, b P<0.05; compared with DYG group, c P<0.05; compared with XPP-L group, d P<0.05; compared with XPP-M group, e P<0.05; compared with XPP-H group, f P<0.05.

[0173] 3.8 Protein expression results of PI3K / Akt / mTOR in uterine tissue of rats in each group

[0174] 3.8.1 PI3K protein expression

[0175] The results are shown in Table 10. Figure 2 Compared with the Control group, the relative expression of PI3K in the Model group was significantly increased, and the difference was statistically significant (P < 0.05). Compared with the Model group, except for the low-dose Xueping Tablets group, the relative expression of PI3K in the uterus of rats in each treatment group decreased to varying degrees, and the difference was statistically significant (P < 0.05). Compared with the Control group, the expression of PI3K in the XPP+DYG group was increased, but the difference was not statistically significant (P > 0.05).

[0176] Comparison between intervention groups: The relative expression of PI3K in the XPP-L group was higher than that in the other intervention groups, and the difference was statistically significant (P < 0.05). Compared with the DYG group, the relative expression of PI3K in the XPP-M group and the XPP-H group was slightly higher, but the difference was not large (P > 0.05). Compared with the XPP-M group, the relative expression of PI3K in the XPP+DYG group was lower, and the difference was statistically significant (P < 0.05).

[0177] 3.8.2 Akt protein expression

[0178] The results are shown in Table 10. Figure 2 Compared with the Control group, the relative expression of Akt in the Model group was significantly increased, and the difference was statistically significant (P < 0.05). Compared with the Model group, except for the low-dose Xueping Tablets group, the relative expression of Akt in the uterus of rats in each treatment group decreased to varying degrees, and the difference was statistically significant (P < 0.05).

[0179] Comparison among intervention groups: Compared with the XPP-L group, the relative expression of Akt in the DYG group, XPP-H group, and XPP+DYG group was significantly lower (P<0.05). Compared with the DYG group, the relative expression of Akt in the XPP-M group and XPP-H group was slightly higher, but the difference was not significant (P>0.05).

[0180] 3.8.3 mTOR protein expression

[0181] The results are shown in Table 10. Figure 2 Compared with the Control group, the relative expression of mTOR in the Model group was significantly increased, and the difference was statistically significant (P < 0.05). Compared with the Model group, the relative expression of mTOR in the uterus of rats in the DYG group, XPP-H group, and XPP+DYG group decreased to varying degrees, and the difference was statistically significant (P < 0.05). Compared with the Control group, the mTOR expression levels in the XPP-M group, XPP-H group, and XPP+DYG group were still high, but the difference was not statistically significant (P > 0.05).

[0182] Comparison between intervention groups: Compared with the XPP-L group, the relative expression of mTOR in the DYG group was decreased, and the difference was statistically significant (P < 0.05).

[0183] The relative expression of mTOR in the DYG group was slightly higher, but there was no significant difference (P>0.05).

[0184] Table 10 Expression of PI3K / Akt / mTOR related proteins in uterine tissue of rats in each group

[0185]

[0186] Note: Compared with the Control group, a P<0.05; compared with the Model group, b P<0.05; compared with DYG group, c P<0.05; compared with XPP-L group, d P<0.05; compared with XPP-M group, e P<0.05; compared with XPP-H group, f P<0.05.

[0187] 3.9 Results of mRNA expression of PI3K / Akt / mTOR in uterine tissue of rats in each group

[0188] 3.9.1 PI3K mRNA expression

[0189] The results are shown in Table 11. Overall trend: Control group < XPP + DYG group < DYG group ≤ XPP-M group < XPP-H group < XPP-L group < Model group.

[0190] Compared with the Control group, the expression of PI3K mRNA in the uterus of rats in each group was significantly increased, and the difference was statistically significant (P < 0.05). Compared with the Model group, the expression of PI3K mRNA in the uterus of rats in each intervention group decreased to varying degrees, and the difference was statistically significant (P < 0.05). Although the expression values ​​of PI3K mRNA in each intervention group decreased, they were still higher than those in the Control group, and the difference was statistically significant (P < 0.05).

[0191] Comparison among intervention groups: The uterine PI3K mRNA expression value of the XPP+DYG group was significantly lower than that of the other intervention groups, and the difference was statistically significant (P < 0.05). Compared with the XPP-L group, the PI3K mRNA expression value of the DYG group was significantly reduced, and the difference was statistically significant (P < 0.05). There was no statistically significant difference between the DYG group and the XPP-M group (P > 0.05). There was no statistically significant difference between the XPP-M group and the XPP-H group (P > 0.05).

[0192] 3.9.2 Akt mRNA expression

[0193] The results are shown in Table 11. Compared with the Control group, the expression of Akt mRNA in the uterus of rats in each group was significantly increased, and the difference was statistically significant (P < 0.05). Compared with the Model group, the expression of Akt mRNA in the uterus of rats in each intervention group was significantly decreased, and the difference was statistically significant (P < 0.05). Although the expression values ​​of Akt mRNA in each intervention group were reduced, they were still higher than those in the Control group, and the difference was statistically significant (P < 0.05).

[0194] Comparison among intervention groups: The expression of Akt mRNA in the uterus of rats in the XPP+DYG group was significantly lower than that in the other intervention groups (P<0.05). Compared with the XPP-L group, the expression of Akt mRNA in the DYG group was significantly reduced, and the difference was statistically significant (P<0.05). There was no statistically significant difference between the DYG group and the XPP-M group (P>0.05). There was no statistically significant difference between the XPP-M group and the XPP-H group (P>0.05).

[0195] 3.9.3 mTOR mRNA expression

[0196] The results are shown in Table 11. Compared with the Control group, the expression of mTOR mRNA in the uterus of rats in each group was significantly increased, and the difference was statistically significant (P < 0.05). Compared with the Model group, except for the XPP-L group, the expression of mTOR mRNA in the uterus of rats in each intervention group was significantly decreased, and the difference was statistically significant (P < 0.05). Although the mTOR mRNA expression values ​​of each intervention group decreased, they were still higher than those of the Control group, and the difference was statistically significant (P < 0.05).

[0197] Comparison among intervention groups: The mTOR mRNA expression value in the uterus of rats in the XPP+DYG group was significantly lower than that in the other intervention groups, and the difference was statistically significant (P < 0.05). Compared with DYG, the mTOR mRNA expression value in the XXP-L group increased significantly, and the difference was statistically significant (P < 0.05). Compared with the XXP-L group, the mTOR mRNA expression values ​​in the XPP-M group and the XPP-H group decreased significantly, and the difference was statistically significant (P < 0.05). There was no statistically significant difference between the XPP-M group and the XPP-H group (P > 0.05). There was no statistically significant difference between the DYG group and the XPP-M group (P > 0.05).

[0198] Table 11 Relative expression changes of PI3K / Akt / mTOR pathway-related mRNA in uterine tissue of rats in each group

[0200]

[0201] Note: Compared with the Control group, a P<0.05; compared with the Model group, b P<0.05; compared with DYG group, c P<0.05; compared with XPP-L group, d P<0.05; compared with XPP-M group, e P<0.05; compared with XPP-H group, f P<0.05.

[0202] In summary, the present invention has found through animal experiments that Xueping tablets can effectively improve the general condition of rats with endometrial hyperplasia, reduce the endometrial thickness, gland number and other endometrial conditions of rats with endometrial hyperplasia, reduce the levels of IL-6 and TNF-α inflammatory factors, and reduce estrogen. This improvement may be achieved by regulating the PI3K / Akt / mTOR signaling pathway, downregulating PI3K, Akt, mTOR protein and mRNA expression, reducing inflammatory factors, regulating immune response, maintaining balance, and thus achieving the therapeutic purpose.

[0203] Finally, it should be noted that the above content is only used to illustrate the technical solution of the present invention, rather than to limit the scope of protection of the present invention. Simple modifications or equivalent substitutions of the technical solution of the present invention by ordinary technicians in this field do not deviate from the essence and scope of the technical solution of the present invention.

Claims

1. Use of Xueping tablets in the preparation of medicines for treating endometrial hyperplasia.

2. The use according to claim 1, characterized in that The dosage of the blood-level tablet is about 500-1 g / kg / d.

3. The use according to claim 2, characterized in that: The dosage of the blood-level tablet is about 1 g / kg / d.

4. Use of Xueping Tablets in combination with dydrogesterone in the preparation of a drug for treating endometrial hyperplasia.

5. The use according to claim 4, characterized in that The dosage of the blood-level tablet is about 500- 1000 mg / kg / d, the daily dose of dydrogesterone is approximately 2.09 mg / kg / d.

6. The use according to claim 4, characterized in that The dosage of the blood level tablet is about 500 mg / kg / d, and the daily dosage of dydrogesterone is about 2.09 mg / kg / d.

7. A pharmaceutical composition, characterized in that Including blood level tablets and dydrogesterone.

8. The pharmaceutical composition according to claim 7, characterized in that The pharmaceutical composition includes pharmaceutically acceptable excipients.

9. The pharmaceutical composition according to claim 7, characterized in that The dosage form of the pharmaceutical composition is tablets, pills, dripping pills, capsules, granules, powders, granules, pastes, solutions, suspensions, sprays, drops, and emulsions.

10. The pharmaceutical composition according to claim 9, characterized in that The dosage form of the pharmaceutical composition is tablet, capsule, granule, powder or solution.

Citation Information

Patent Citations

  • Application of Xueping tablets in preparation of medicines for treating uterine ectopic diseases

    CN111012848A

  • Method for preparing medicament for treating uterine bleeding

    CN102327401A

  • Preparation method of pharmaceutical composition Xueping for treating metrorrhagia and metrostaxis

    CN104547317A

  • Application of Xueping preparation in preparing medicines for treating hysteromyoma

    CN111265602A

  • Traditional Chinese medicine composition for clearing heat, dispersing blood stasis, stopping bleeding and regulating menstruation and preparation method thereof

    CN117582468A